WallStreetZenWallStreetZen

NASDAQ: ACAD
Acadia Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ACAD

Based on 18 analysts offering 12 month price targets for Acadia Pharmaceuticals Inc

Min Forecast
$17.00-28.09%
Avg Forecast
$30.17+27.61%
Max Forecast
$39.00+64.97%

Should I buy or sell ACAD stock?

Based on 18 analysts offering ratings for Acadia Pharmaceuticals Inc.

Buy
Strong Buy
5 analysts 27.78%
Buy
8 analysts 44.44%
Hold
4 analysts 22.22%
Sell
0 analysts 0%
Strong Sell
1 analysts 5.56%
Our proven Zen Rating quant model agrees with analyst consensus with a "Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their ACAD stock forecasts and price targets.

ACAD stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-06
lockedlocked$00.00+00.00%2025-11-06
lockedlocked$00.00+00.00%2025-10-21
lockedlocked$00.00+00.00%2025-09-29
lockedlocked$00.00+00.00%2025-09-11
UBS
Top 16%
85
Strong BuyMaintains$39.00+64.97%2025-09-09
Bank of America
Top 22%
79
HoldMaintains$27.00+14.21%2025-08-07
Goldman Sachs
Top 23%
78
Strong SellMaintains$17.00-28.09%2025-08-07
Mizuho
Top 29%
72
HoldMaintains$24.00+1.52%2025-08-07
JMP Securities
Top 43%
58
BuyMaintains$35.00+48.05%2025-08-07

1 of 2

Forecast return on equity

Is ACAD forecast to generate an efficient return?

Company
37.71%
Industry
286.15%
Market
234.29%
ACAD's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ACAD forecast to generate an efficient return on assets?

Company
25.99%
Industry
98.34%
ACAD is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ACAD earnings per share forecast

What is ACAD's earnings per share in the next 3 years based on estimates from 23 analysts?

Avg 1 year Forecast
$0.58-62.84%
Avg 2 year Forecast
$0.88-44.25%
Avg 3 year Forecast
$1.26-19.98%
ACAD's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

ACAD revenue forecast

What is ACAD's revenue in the next 3 years based on estimates from 23 analysts?

Avg 1 year Forecast
$1.1B+4.38%
Avg 2 year Forecast
$1.2B+16.7%
Avg 3 year Forecast
$1.3B+28.64%
ACAD's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ACAD earnings growth forecast

How is ACAD forecast to perform vs Biotechnology companies and vs the US market?

Company
-7.61%
Industry
48.92%
Market
43.3%
ACAD's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
ACAD's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
ACAD's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

ACAD revenue growth forecast

How is ACAD forecast to perform vs Biotechnology companies and vs the US market?

Company
8.78%
Industry
104.73%
Market
25.61%
ACAD's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ACAD's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ACAD vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ACAD$23.64$30.17+27.61%Buy
IMVT$22.82$26.40+15.69%Buy
LGND$201.27$233.75+16.14%Strong Buy
CRNX$41.43$74.38+79.52%Buy
NAMS$36.42$44.00+20.81%Strong Buy
View Top Biotech Stocks

Acadia Pharmaceuticals Stock Forecast FAQ

Is Acadia Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 18 Wall Street analysts covering (NASDAQ: ACAD) stock is to Buy ACAD stock.

Out of 18 analysts, 5 (27.78%) are recommending ACAD as a Strong Buy, 8 (44.44%) are recommending ACAD as a Buy, 4 (22.22%) are recommending ACAD as a Hold, 0 (0%) are recommending ACAD as a Sell, and 1 (5.56%) are recommending ACAD as a Strong Sell.

If you're new to stock investing, here's how to buy Acadia Pharmaceuticals stock.

What is ACAD's earnings growth forecast for 2025-2027?

(NASDAQ: ACAD) Acadia Pharmaceuticals's forecast annual earnings growth rate of -7.61% is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 48.92%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 43.3%.

Acadia Pharmaceuticals's earnings in 2025 is $261,174,000.On average, 23 Wall Street analysts forecast ACAD's earnings for 2025 to be $98,700,672, with the lowest ACAD earnings forecast at $64,661,290, and the highest ACAD earnings forecast at $181,193,726. On average, 23 Wall Street analysts forecast ACAD's earnings for 2026 to be $148,084,844, with the lowest ACAD earnings forecast at $69,804,418, and the highest ACAD earnings forecast at $342,846,952.

In 2027, ACAD is forecast to generate $212,543,117 in earnings, with the lowest earnings forecast at $44,765,509 and the highest earnings forecast at $442,325,861.

What is ACAD's revenue growth forecast for 2025-2027?

(NASDAQ: ACAD) Acadia Pharmaceuticals's forecast annual revenue growth rate of 8.78% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 104.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.61%.

Acadia Pharmaceuticals's revenue in 2025 is $1,047,118,000.On average, 23 Wall Street analysts forecast ACAD's revenue for 2025 to be $184,915,725,981, with the lowest ACAD revenue forecast at $175,949,089,680, and the highest ACAD revenue forecast at $193,374,816,831. On average, 23 Wall Street analysts forecast ACAD's revenue for 2026 to be $206,740,180,374, with the lowest ACAD revenue forecast at $185,592,453,249, and the highest ACAD revenue forecast at $235,670,271,081.

In 2027, ACAD is forecast to generate $227,887,907,499 in revenue, with the lowest revenue forecast at $199,634,544,060 and the highest revenue forecast at $268,322,361,762.

What is ACAD's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: ACAD) forecast ROA is 25.99%, which is lower than the forecast US Biotechnology industry average of 98.34%.

What is ACAD's Price Target?

According to 18 Wall Street analysts that have issued a 1 year ACAD price target, the average ACAD price target is $30.17, with the highest ACAD stock price forecast at $39.00 and the lowest ACAD stock price forecast at $17.00.

On average, Wall Street analysts predict that Acadia Pharmaceuticals's share price could reach $30.17 by Nov 6, 2026. The average Acadia Pharmaceuticals stock price prediction forecasts a potential upside of 27.61% from the current ACAD share price of $23.64.

What is ACAD's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: ACAD) Acadia Pharmaceuticals's current Earnings Per Share (EPS) is $1.57. On average, analysts forecast that ACAD's EPS will be $0.58 for 2025, with the lowest EPS forecast at $0.38, and the highest EPS forecast at $1.07. On average, analysts forecast that ACAD's EPS will be $0.88 for 2026, with the lowest EPS forecast at $0.41, and the highest EPS forecast at $2.03. In 2027, ACAD's EPS is forecast to hit $1.26 (min: $0.26, max: $2.61).

What is ACAD's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: ACAD) forecast ROE is 37.71%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.